Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 3/20 | 0.44 |
| ▸ | MGAM | O43451 | 1/20 | 0.44 |
| ▸ | SI | P14410 | 1/20 | 0.44 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.41 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.41 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.38 |
| ▸ | CYP4F2 | P78329 | 2/20 | 0.38 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.38 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.37 |
| ▸ | PGR | P06401 | 1/20 | 0.37 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.37 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.37 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | POLB | P06746 | 2/20 | 0.36 |
| ▸ | TSHR | P16473 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3590180 | 0.88 | CYP1A2 (0.52) | CYP1A2GAAMGAMSIMGAM2 | |
| SCHEMBL11907952 | 0.83 | CYP1A2 (0.48) | CYP1A2GAAMGAMSIMGAM2 | |
| SCHEMBL10643442 | 0.81 | CYP1A2 (0.47) | CYP1A2GAAMGAMSIMGAM2 | |
| SCHEMBL9493128 | 0.80 | GAA (0.50) | CYP1A2GAAMGAMSIMGAM2 | |
| SCHEMBL9913959 | 0.78 | CYP1A2 (0.48) | CYP1A2GAAMGAMSIMGAM2 | |
| Succinic Acid Diethyl Ester SCHEMBL28738178 | 0.78 | GAA (0.52) | CYP1A2GAAMGAMSIMGAM2 | |
| SCHEMBL1411856 | 0.77 | CYP1A2 (0.47) | CYP1A2GAAMGAMSIMGAM2 | |
| SCHEMBL14900199 | 0.75 | CYP1A2 (0.55) | CYP1A2GAAMGAMSIMGAM2 | |
| SCHEMBL10643440 | 0.75 | CYP1A2 (0.45) | CYP1A2GAAMGAMSIMGAM2 | |
| Succinic Acid Diethyl Ester SCHEMBL22780 | 0.74 | GAA (0.67) | CYP1A2GAAMGAMSIMGAM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100190753-A1 | Methods and Compositions for Treating Amyloid-Related Diseases | BELLUS HEALTH (INTERNATIONAL) LIMITED (CH) | 2010-07-29 | — | — | US | disclosed |
| US-7598269-B2 | Methods and compositions for treating amyloid-related diseases | BELLUS HEALTH (INTERNATIONAL) LIMITED (CH) | 2009-10-06 | — | — | US | disclosed |
| US-20080015180-A1 | Methods and compositions for treating amyloid-related diseases | NEUROCHEM (INTERNATIONAL) LIMITED (CH) | 2008-01-17 | — | — | US | disclosed |
| US-20060135403-A1 | Therapeutic formulations for the treatment of beta-amyloid related diseases | NEUROCHEM (INTERNATIONAL) LIMITED (CH) | 2006-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100190753-A1 | Methods and Compositions for Treating Amyloid-Related Diseases | APP, PSEN1, PSEN2 | CYP1A2 2127/4885GAA 21/4885MGAM 197/4885 |
| US-20060135403-A1 | Therapeutic formulations for the treatment of beta-amyloid related diseases | APP, IAPP, BACE1 | CYP1A2 3545/4885GAA 181/4885MGAM 521/4885 |
| US-20080015180-A1 | Methods and compositions for treating amyloid-related diseases | APP, PSEN1, PSEN2 | CYP1A2 2127/4885GAA 21/4885MGAM 197/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.